<DOC>
	<DOCNO>NCT00353366</DOCNO>
	<brief_summary>GSK submit registration file live attenuate oral human rotavirus ( HRV ) vaccine several country . In view registration Philippines , present study collect data safety vaccine local target population per Bureau Food Drugs Directive .</brief_summary>
	<brief_title>To Evaluate Safety &amp; Reactogenicity GSK Bio 's Human Rotavirus ( HRV ) Vaccine Filipino Infants Least 6 Weeks Age First Vaccination</brief_title>
	<detailed_description>The protocol amend reflect change prescribe information . The age infant change 6 - 14 week least 6 week time first vaccination . This protocol post amend order comply FDA AA .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol ( e.g . completion diary card , return followup visit ) enrol study . A Filipino male female age least 6 week time first vaccination . Written inform consent obtain parent guardian subject . History allergic disease reaction likely exacerbate component vaccine . Any history chronic gastrointestinal disease include uncorrected congenital malformation GI tract . Any contraindication state Prescribing Information .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>24 Weeks</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>safety</keyword>
	<keyword>Post-marketing surveillance ( PMS )</keyword>
	<keyword>Rotarix</keyword>
	<keyword>oral</keyword>
	<keyword>Filipino</keyword>
	<keyword>Rotavirus</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Human Rotavirus ( HRV ) vaccine</keyword>
</DOC>